Therapure Biopharma has been selected as a subcontractor for DynPort Vaccine Co. LLC (DVC), which was awarded a contract with a maximum value of $157.3 million by the U.S. Department of Defense to support the development of a prophylactic countermeasure to prevent the effects of organophosphorus nerve agent poisoning.  

Therapure’s subcontract includes process optimization as well as manufacture of all clinical and nonclinical materials to support DVC’s contract to develop, test and obtain FDA approval for human plasma-derived butyrylcholinesterase (HuBChE), a blood plasma protein that binds and inactivates nerve agents.

Mr. Nick Green, Therapure’s president and chief executive officer, said, “We are delighted to partner with DVC to develop and manufacture medical counter measures for the U.S. Department of Defense as part of a defense strategy against a wide range of nerve gases. Therapure successfully completed a rigorous selection and approval process to serve as the manufacturing subcontractor under the prime contract, which is a testament to the Company’s standards and capabilities in biomanufacturing. It is an honor to be part of this very critical initiative to protect U.S. Servicemen and women.”